Literature DB >> 2789071

Divided-dose kinetics of mefloquine in man.

G Franssen1, B Rouveix, J Lebras, J Bauchet, F Verdier, C Michon, F Bricaire.   

Abstract

The kinetics of mefloquine was investigated following oral divided-doses in 10 healthy Caucasian volunteers. They received 500 or 750 mg followed by 500 mg 8 h later. Unchanged mefloquine (M) and its carboxylic acid metabolite (MM) were measured in whole blood and plasma for 50 days by h.p.l.c. Maximum blood and plasma M concentrations of 1872 +/- 362 ng ml-1 (mean +/- s.d.) and 1900 +/- 434 ng ml-1, respectively, were found within 6-10 h after the second dose. The terminal plasma elimination half-life was 20.1 +/- 3.7 days (mean +/- s.d.) and the oral clearance was 22.3 +/- 6.7 ml h-1 kg-1 (mean +/- s.d.). Plasma concentrations of MM exceeded those of M by 2-3 fold within 2 days. The whole blood concentration of MM was lower than that in plasma but also exceeded the whole blood concentration of M.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2789071      PMCID: PMC1379902          DOI: 10.1111/j.1365-2125.1989.tb05413.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  Mefloquine and an acute brain syndrome.

Authors:  B Rouveix; F Bricaire; C Michon; G Franssen; J Lebras; J Bernard; F Ajana; J L Vienne
Journal:  Ann Intern Med       Date:  1989-04-01       Impact factor: 25.391

2.  Kinetics of a new antimalarial, mefloquine.

Authors:  R E Desjardins; C L Pamplin; J von Bredow; K G Barry; C J Canfield
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

3.  On the mechanism for the red-cell accumulation of mefloquine, an antimalarial drug.

Authors:  R C San George; R L Nagel; M E Fabry
Journal:  Biochim Biophys Acta       Date:  1984-03-23

4.  Single dose kinetics of mefloquine in man. Plasma levels of the unchanged drug and of one of its metabolites.

Authors:  D E Schwartz; G Eckert; D Hartmann; B Weber; D Richard-Lenoble; J M Ekue; M Gentilini
Journal:  Chemotherapy       Date:  1982       Impact factor: 2.544

5.  The antimalarial drug mefloquine binds to membrane phospholipids.

Authors:  R Chevli; C D Fitch
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

6.  Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine.

Authors:  J Karbwang; S Looareesuwan; R E Phillips; Y Wattanagoon; M E Molyneux; B Nagachinta; D J Back; D A Warrell
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

7.  Analysis of the antimalarial, mefloquine, in blood and plasma using high-performance liquid chromatography.

Authors:  I M Kapetanovic; J D DiGiovanni; J Bartosevich; V Melendez; J Von Bredow; M Heiffer
Journal:  J Chromatogr       Date:  1983-10-14

8.  Intragastric mefloquine is absorbed rapidly in patients with cerebral malaria.

Authors:  P Chanthavanich; S Looareesuwan; N J White; D A Warrell; M J Warrell; J H DiGiovanni; J von Bredow
Journal:  Am J Trop Med Hyg       Date:  1985-11       Impact factor: 2.345

9.  Trials of mefloquine in vivax and of mefloquine plus 'fansidar' in falciparum malaria.

Authors:  T Harinasuta; D Bunnag; R Lasserre; R Leimer; S Vinijanont
Journal:  Lancet       Date:  1985-04-20       Impact factor: 79.321

10.  [Curative treatment of malaria Plasmodium falciparum, P. vivax and P. ovale malaria with mefloquine].

Authors:  M Danis; H Felix; G Brucker; P Druilhe; A Datry; D Richard-Lenoble; M Gentilini
Journal:  Med Trop (Mars)       Date:  1982 Jul-Aug
View more
  14 in total

1.  Pharmacokinetics of mefloquine in the presence of primaquine.

Authors:  J Karbwang; K Na Bangchang; A Thanavibul; D J Back; D Bunnag
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Effect of ampicillin on mefloquine pharmacokinetics in Thai males.

Authors:  J Karbwang; K Na Bangchang; D J Back; D Bunnag
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Population pharmacokinetics of mefloquine in military personnel for prophylaxis against malaria infection during field deployment.

Authors:  B G Charles; A Blomgren; P E Nasveld; S J Kitchener; A Jensen; R M Gregory; B Robertson; I E Harris; M P Reid; M D Edstein
Journal:  Eur J Clin Pharmacol       Date:  2007-01-11       Impact factor: 2.953

4.  Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study.

Authors:  F Nosten; J Karbwang; N J White; K Na Bangchang; D Bunnag; T Harinasuta
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

Review 5.  Clinical pharmacokinetics of mefloquine.

Authors:  J Karbwang; N J White
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

6.  Distribution of mefloquine in the blood of Thai patients with acute uncomplicated falciparum malaria following administration of therapeutic doses of artesunate.

Authors:  Kesara Na-Bangchang; Ronnatrai Ruengweerayut; Walther H Wernsdorfer
Journal:  Eur J Clin Pharmacol       Date:  2011-05-10       Impact factor: 2.953

7.  Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.

Authors:  S M D K Ganga Senarathna; Kevin T Batty
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

Review 8.  Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  K J Palmer; S M Holliday; R N Brogden
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

9.  Influence of hemodialysis on plasma concentration-time profiles of mefloquine in two patients with end-stage renal disease: a prophylactic drug monitoring study.

Authors:  C A Crevoisier; I Joseph; M Fischer; H Graf
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

10.  Pharmacokinetics of mefloquine combined with artesunate in children with acute falciparum malaria.

Authors:  R Price; J A Simpson; P Teja-Isavatharm; M M Than; C Luxemburger; D G Heppner; T Chongsuphajaisiddhi; F Nosten; N J White
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.